drugset / Trial / NCT02068586
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Phase 2
Active not recruiting
210 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.
Timeline
- Start
- 2014-11-19
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | — | Oral |
| Subject | Valproic Acid | Small molecule | — | Oral |